Together, we can improve the lives of breast cancer patients everywhere
Our founders are recognized leaders in the field of genomics. Their prominent roles at comprehensive cancer centers put Agendia in an excellent position to partner with the academic world.
MARK R. STRALEY
CHIEF EXECUTIVE OFFICER (CEO)
Mr. Mark R. Straley joined Agendia Inc. in August 2015 as the company’s CEO, bringing more than 25 years of international experience developing and commercializing clinical diagnostics and laboratory services. Most recently he served as President, Anatomical Pathology of Thermo Fisher Scientific of Waltham, Massachusetts. Prior to this position he was President and CEO of Metamark Genetics of Cambridge, Massachusetts, a biotech company focusing on the development of prognostic and predictive diagnostic tests for personalized treatment of cancer patients. From 2005 to 2010, Mark held positions at Ortho Clinical Diagnostics, a J&J company, first as Worldwide Vice President of Marketing and then as Worldwide President. Prior to his assignment with J&J, Mark worked for such brand name companies as Bayer Healthcare and Abbott Laboratories where he held positions of increasing responsibility. Mark earned a Bachelor of Science degree in Marketing from Miami University.
Mark R. Straley
CHIEF FINANCIAL OFFICER (CFO)
CHIEF OPERATING OFFICER (COO)
Kurt joined Agendia in March of 2012 and has more than fifteen years of experience in financial management and analytics in healthcare, banking and aerospace industries. His previous public company experience has been at Alphatec Spine, Wells Fargo and UTC Aerospace. Kurt holds a Master’s of Science in Business Administration degree from San Diego State University with a focus on Finance and a Bachelor of Science degree in Finance from the University of Wisconsin-Milwaukee.
Chief Financial Officer (CFO)
Brian Dow joined Agendia in June 2020 as Chief Financial Officer with more than 25 years of financial, accounting and operations experience with a focus on public and emerging life sciences companies. Most recently, Brian served as Chief Financial Officer & Senior Vice President, Finance and Administration of Pulse Biosciences, a medical technology company developing a novel energy-based tissue treatment platform. Prior to that role, he was the Vice President and Principal Accounting Officer of Pacific Biosciences of California, a leading provider of next generation genetic sequencing instruments. In addition, Brian held a series of financial officer positions, more recently serving as the Chief Financial Officer with Northstar Neuroscience, Inc., a development stage medical device company. Brian began his career as a manager with Ernst and Young after earning his Bachelor of Science degree in Management from the Georgia Institute of Technology. Brian is also recognized as a licensed Certified Public Accountant by the Washington State Board of Accountancy.
WILLIAM AUDEH, MD, MS
CHIEF MEDICAL OFFICER (CMO)
Dr. William Audeh is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles, where he continues to be a member of the Medical Staff. Prior to joining Agendia, and in addition to his clinical practice, he served as the former Director of the Cedars-Sinai Cancer Center and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh also served as Director of the Medical Oncology Training Program for Breast Surgery and Surgical Oncology Fellowships at Cedars-Sinai, and is Associate Clinical Professor of Medicine at the UCLA David Geffen School of Medicine. Dr. Audeh has been Principal Investigator on a wide variety of national and international clinical and translational trials, and has authored numerous publications in the field of breast cancer, cancer genomics, and targeted cancer therapy.
Dr. Audeh received his medical degree from the University of Iowa and an M.S. Degree in Genetics from the University of Minnesota. He went on to complete his residency in Internal Medicine as well as a fellowship in Medical Oncology at Stanford University Medical Center. He is board certified on internal medicine and medical oncology, and is a member of the American Society of Clinical Oncology and American Association of Cancer Research.
William Audeh, MD, MS
PROF. LAURA VAN ‘T VEER, PhD
CHIEF RESEARCH OFFICER (CRO) AND CO‑FOUNDER
Prof. Laura van ‘t Veer, PhD, is co‑founder of Agendia and serves as its Chief Research Officer. As one of the world’s leading innovators in cancer diagnostics, she is widely recognized as a pioneer in the field of personalized medicine, also known as precision medicine. She has a 20-year track record in molecular oncology research, which includes more than 230 scientific publications and prestigious awards for her contributions to breast cancer care.
Dr. van ‘t Veer is best known for work stemming from a discovery she and her team made at the Netherlands Cancer Institute (NKI). They established that a specific DNA signature made up of 70 genes distinguished whether breast cancer tumors had a low or high risk of recurrence. After patenting their innovation, she and research partner René Bernards founded Agendia and launched the MammaPrint test.
In 2010, Dr. van ‘t Veer was appointed Professor of Laboratory Medicine and Director of Applied Genomics at the University of California San Francisco. She is also the former head of the NKI’s DNA-diagnostic laboratory. She was awarded a 2014 European Union Prize for Women Innovators that acknowledges the ways MammaPrint has helped transform breast cancer care. In 2015, the European Patent Office (EPO) recognized MammaPrint’s impact on breast cancer diagnostics by honoring Dr. van ‘t Veer with a European Inventor Award.
Prof. Laura van ‘t Veer, PhD
PROF. DR. RENÉ BERNARDS, PhD
CHIEF SCIENTIFIC OFFICER (CSO) AND CO‑FOUNDER
Prof. Dr. René Bernards is Chief Scientific Officer of Agendia and also a co‑founder of the Company. René has a 30-year track record in oncology research, with more than 150 published papers in peer-reviewed journals. He is the Head of Division of Molecular Carcinogenesis of the Netherlands Cancer Institute, professor of Molecular Carcinogenesis at Utrecht University and member of the Royal Netherlands Academy of Arts and Sciences (KNAW). In addition René is a member of the Scientific Advisory Board of Gilde Healthcare fund.
Prof. Dr. René Bernards, PhD
BASTIAAN VAN DER BAAN
CHIEF CLINICAL AND BUSINESS DEVELOPMENT OFFICER
Bas van der Baan is Chief Clinical and Business Development Officer at Agendia and joined the Company shortly after its founding in 2003. Bas holds a degree in molecular sciences and has over 15 years of healthcare experience in commercial roles, and has held positions at Unilever and other biotechnology start-ups.
Bastiaan Van Der Baan
CHIEF COMMERCIAL OFFICER
Wendy joined Agendia in May 2019 and brings 20 years of success in launching, relaunching and leading commercial organizations in diagnostic, surgical and capital sales, with a focus in Oncology and Women’s Health. She also comes with extensive experience in marketing, corporate advocacy and sales training.
Wendy’s career history includes working at Animated Dynamics, Strand Diagnostics, Biodesix, Integrated Oncology, and Cytyc Corporation. Most recently, Wendy served as CCO for Animated Dynamics, an imaging company that delivers drug assessments in 3D living tissue samples. Prior to that, Wendy served as CCO with Biodesix, where she relaunched VeriStrat and brought the GeneStrat test to market, both of which resulted in continuous record growth.
Previous to Biodesix, Wendy served as VP of Sales with Integrated Oncology, and her responsibilities included successfully integrating US Labs and Genzyme Genetics under one umbrella.
Wendy’s tenure with Precision Therapeutics included national sales roles and a relaunch of the company’s ChemoFx product, which helped lead to large expansion of the company’s revenue growth. Wendy also has start up experience with Vermillion and Cytyc Corporation (now Hologic).
Wendy is based out of Ohio and holds a Master of Science from the University of West Virginia and a Bachelor of Science from Marietta College.
CHIEF STRATEGY OFFICER AND HEAD OF BUSINESS DEVELOPMENT
Roopom is a life science business leader with 20 years’ experience covering strategy, financial advisory, operational and scientific roles. He has broad experience with startups to global Fortune 500 companies advising on corporate strategy, portfolio design, product development and commercialization, financing, partnerships and acquisitions. Most recently, he was President and CEO of RainDance Technologies (acquired by BioRad Labs) and led the company to become a pioneer in Liquid Biopsy for detecting cancer from a blood test.
Previously, Roopom led teams at McKinsey, Leerink and Goldman Sachs where he completed 80+ healthcare transactions raising over $10Bn in capital financings, 30+ IPOs, and 20+ M&A transactions. His earlier career spanned scientific cancer research at the Dana Farber Cancer Institute and Human Genome Project.
A biochemist and economist by training, Roopom has a graduate degree from Harvard and two undergrad degrees from MIT where he was elected a Howard Hughes Medical Institute Scholar.
Board of Directors
PATRICK J. BALTHROP, SR
Patrick J. Balthrop is the Founding Principal of Apalachee Ventures, LLC, an investment and advisory firm. He currently serves as Chairman of Discovery Life Sciences, Chairman and Director at Oxford Immunotec (NASDAQ: OXFD), as well as Director at Personalis, Inc. (NASDAQ: PSNL). Patrick previously held the position of CEO, President and Director at Luminex Corporation (NASDAQ: LMNX), and President of Fisher Healthcare (then Fisher Scientific). He has also held a number of positions within Abbott Laboratories, including President of Abbott Vascular and Corporate VP, Worldwide Commercial Operations. Patrick has an MBA from the Kellogg School of Management, Northwestern University and a BS in Biology from Spring Hill College.
SUPERVISORY BOARD MEMBER, MEMBER OF THE AUDIT COMMITTEE, MEMBER OF THE TECHNICAL COMMITTEE AND MEMBER OF THE GOVERNANCE AND REMUNERATION COMMITTEE
Christoph is an investment manager at Korys, focusing on the fund investments in the life science sector in both the private and public equity market. In this capacity, he currently represents Korys on the board of MyCartis. Prior to that, he was active as a Junior Analyst in the Paris offices of Fortis Bank (now BNP Paribas) at the Corporate Finance and Capital Markets department. He then joined iPierian, a San Francisco biotech start-up company, as a financial analyst.
SUPERVISORY BOARD MEMBER
Laurie brings more than 30 years of executive leadership experience and an exceptional track record in the development of new business channels and global marketing strategies within the life sciences arena. Recently, she held the position as President of CrownBio Global Life Science and Diagnostic Solutions Division, leading worldwide sales and marketing into explosive growth and global brand recognition. Her efforts helped transform CrownBio into a prominent global player in the pre-clinical oncology and CVMD service markets with more than 35% growth throughout her tenure. Heilmann’s expertise includes leading initiatives in biotech, drug development, medical devices, and healthcare technologies across diverse therapeutic backgrounds including oncology, CNS and CVMD. With Heilmann’s multifaceted experience of leading projects from concept to commercialization, along with her vast knowledge of FDA and sponsor requirements in the US, Europe, India, and Asia, she will be key to accelerating Agendia’s growth in the precision medicine space.
SUPERVISORY BOARD MEMBER, MEMBER OF THE GOVERNANCE & REMUNERATION COMMITTEE
Peter Stein is the Chairman and Chief Executive Officer and principal shareholder of Norgine, an independent, specialty pharmaceutical company with operations throughout Europe. Prior to joining Norgine in 1987, Peter was a co‑founder and Vice President of Invitron Corporation, a contract biomanufacturer formed as a spin-off from the Monsanto Company. He started his pharmaceutical career with Centocor.
SUPERVISORY BOARD MEMBER
Dr. Ferré, a leader in cancer research, developed one of the first quantitative PCR assays in the late 80s while working at the Immune Response Corporation developing novel therapeutic vaccines. Along with authoring two best-sellers, The Polymerase Chain Reaction with Dr. Kary Mullis and Dr. Richard Gibbs and Gene Quantification, he co-founded Althea Technologies in 1998, leading the company as co-CEO for ten years. After the successful acquisition of Althea by Ajinomoto in 2013, Dr. Ferré remains Director of the new entity: AJI Bioservices. Dr. Ferré serves as co-Founder, former CEO/Chairman and current Director of AltheaDx, and a Managing Director of Mesa Verde Venture Partners, a micro fund specializing in early stage life sciences companies and co-CEO of Alma Life Sciences. Dr. Ferré also serves on the Board of La Jolla Institute, a world leader in immunology research and is a member of the Board of the Chopra Foundation’s Executive Committee. He received his PhD in molecular oncology from the Pasteur Institute, France, completed his post-doctoral training at the University of California, San Diego and was the winner of the 2005 E&Y Regional Entrepreneur of the Year Award in the Life Sciences category. In 2016, Dr. Ferré was inducted into the CONNECT Entrepreneur Hall of Fame.
SUPERVISORY BOARD MEMBER
Erik Esveld acquired a Master of Science Degree in Econometrics from Erasmus University in Rotterdam. Since 2001, Erik has been the CFO at Van Herk Groep, based in Rotterdam, The Netherlands.
IVDMIA = in vitro diagnostic multivariate index assay†
Next-generation sequencing is a newer form of DNA sequencing technology. In addition to reducing the costs and time to sequence DNA, sequencing can be conducted with smaller samples.